Bank Pictet & Cie Europe AG Lowers Holdings in Natera, Inc. (NASDAQ:NTRA)

Bank Pictet & Cie Europe AG reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 52.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,979 shares of the medical research company’s stock after selling 2,163 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Natera were worth $251,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of NTRA. Itau Unibanco Holding S.A. purchased a new position in shares of Natera during the 2nd quarter valued at approximately $28,000. Quarry LP raised its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares during the period. GAMMA Investing LLC boosted its stake in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares in the last quarter. Tobam acquired a new stake in shares of Natera during the 2nd quarter valued at about $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of Natera in the 1st quarter valued at about $83,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Natera news, CEO Steven Leonard Chapman sold 4,084 shares of the firm’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $419,712.68. Following the completion of the sale, the chief executive officer now owns 206,293 shares of the company’s stock, valued at $21,200,731.61. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Michael Burkes Brophy sold 690 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $105.29, for a total value of $72,650.10. Following the transaction, the chief financial officer now directly owns 75,810 shares in the company, valued at approximately $7,982,034.90. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 4,084 shares of the stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $419,712.68. Following the transaction, the chief executive officer now directly owns 206,293 shares of the company’s stock, valued at $21,200,731.61. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 49,396 shares of company stock valued at $5,907,764. 7.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NTRA. TD Cowen raised their price objective on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. The Goldman Sachs Group lifted their price target on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Thursday, October 17th. UBS Group decreased their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, Piper Sandler reissued an “overweight” rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $124.44.

Natera Price Performance

NASDAQ:NTRA opened at $119.95 on Wednesday. The stock has a 50 day moving average price of $123.43 and a 200 day moving average price of $110.98. The stock has a market cap of $14.73 billion, a PE ratio of -38.45 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a one year low of $36.90 and a one year high of $133.54.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the previous year, the firm earned ($0.97) EPS. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. Equities research analysts expect that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.